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Prenatal glucocorticoids are routinely administered to pregnant women at risk of 
preterm delivery in order to improve survival of the newborn. However, in half of the 
cases, birth occurs outside the beneficial period for lung development. Glucocorticoids 
are potent immune modulators and cause apoptotic death of immature T cells, and 
we have previously shown that prenatal betamethasone treatment at doses eliciting 
lung maturation induce profound thymocyte apoptosis in the offspring. Here, we asked 
if there are long-term consequences on the offspring’s immunity after this treatment. 
In the non-obese diabetic mouse model, prenatal betamethasone clearly decreased 
the frequency of pathogenic T  cells and the incidence of type 1 diabetes (T1D). In 
contrast, in the lupus-prone MRL/lpr strain, prenatal glucocorticoids induced changes 
in the T  cell repertoire that resulted in more autoreactive cells. Even though gluco-
corticoids transiently enhanced regulatory T  cell (Treg) development, these cells did 
not have a protective effect in a model for multiple sclerosis which relies on a limited 
repertoire of pathogenic T cells for disease induction that were not affected by prenatal 
betamethasone. We conclude that prenatal steroid treatment, by inducing changes 
in the T cell receptor repertoire, has unforeseeable consequences on development of 
autoimmune disease. Our data should encourage further research to fully understand 
the consequences of this widely used treatment.
Keywords: glucocorticoids, prenatal betamethasone, T cell repertoire, autoimmunity, type 1 diabetes, non-obese 
diabetic mice, experimental autoimmune encephalomyelitis mice, Mrl/lpr
inTrODUcTiOn
Non communicable diseases (NCDs), such as cardiovascular diseases, diabetes, chronic respira-
tory diseases, and others, result from a combination of risk factors and are the leading cause for 
almost 70% of all deaths worldwide (1). Among these, autoimmune diseases are responsible for 
more than 5% deaths every year (2), and their incidence is steadily increasing (3, 4). Emerging 
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evidence suggests that prenatal and early life conditions, such 
as environmental exposure to pollutants, poor nutrition, stress, 
or medical interventions during pregnancy might act as pivotal 
determinants of NCD risk in later life (5). Fetal exposure to 
synthetic glucocorticoids, as consequence of antenatal corti-
costeroid (ACS) administration to the mother, constitutes a 
potentially amendable risk factor. ACS is the most important 
obstetric intervention available to reduce the occurrence and 
severity of respiratory distress syndrome and to improve the 
survival chances in premature infants (6). According to WHO 
recommendations, glucocorticoids (either betamethasone or 
dexamethasone) are given to mothers at risk of preterm birth 
between 24 and 34 weeks of gestation (7). The synthetic gluco-
corticoids cross the placenta and accelerate fetal lung maturation, 
achieving maximum benefit from 24 h to 7 days after administra-
tion (8). After injection, glucocorticoid bioactivity in the fetus 
lasts for several days (9) and can exert long-lasting effects upon 
the hypothalamic–pituitary–adrenal (HPA) axis and cognition 
in children (10, 11). Of note, 30–80% of women with symptoms 
of preterm birth have not delivered 14 days later (12), and more 
than half of the women who received ACS delivered later than 
one week after treatment or after 34  weeks of gestation (13), 
among them one third after gestation week 37 (14). Especially 
this population of neonates is likely to encounter more harm 
than benefits from the prenatal treatment with glucocorticoids.
Known as strong immune modulators, glucocorticoids act 
on a great variety of immune cells and have potent effects on 
the development of T  lymphocytes. Exposure of developing 
thymocytes to glucocorticoids results in apoptotic death of the 
immature CD4+CD8+ double-positive (DP) subset (15), and we 
have previously shown that antenatal betamethasone treatment 
leads to a drastic decrease in the thymus volume and thymocyte 
numbers in the offspring (16). In order to sustain T cell output, 
the thymic niche is promptly replenished by newly imported 
hematogenous early thymic progenitors (17, 18), which will then 
proceed to the rearrangement of their T  cell receptor (TCR) 
creating a highly diverse TCR repertoire and undergo positive 
and negative selection processes: thymocytes bearing non-
functional TCRs or TCR with high affinity for self-peptide:MHC 
are deleted, while T  cells with lower affinity TCRs mature and 
populate the periphery [reviewed in Ref. (19)]. However, even 
in healthy individuals, a number of autoreactive T cells escape 
this central tolerance checkpoint and migrate to the periphery, 
where peripheral tolerance mechanisms are engaged to prevent 
overt autoimmunity. Among these, thymic-derived Foxp3+ Treg 
cells and, in particular, a highly efficient population of Treg cells 
generated perinatally, are essential in preventing multiorgan 
autoimmune disease (20–23).
The delicate process of T  cell repertoire selection may be 
compromised under altered glucocorticoid signaling (24–29), 
and as a consequence may have detrimental long-lasting effects 
on immunopathology and susceptibility to diseases. Therefore, 
we sought to investigate the influence of ACS treatment on the 
development of autoimmunity later in life. Using two mouse 
strains that spontaneously develop autoimmunity, namely 
the lupus-prone MRL/lpr strain and the non-obese diabetic 
(NOD) mouse, and the myelin oligodendrocyte glycoprotein 
(MOG)-induced mouse model for multiple sclerosis [experi-
mental autoimmune encephalomyelitis (EAE)], we provide 
evidence that prenatal betamethasone treatment, by inducing 
changes in the T cell repertoire, can alter the course of autoim-
mune disease.
MaTerials anD MeThODs
Mice and Treatment
C57BL/6J, MRL/MpJ-Faslpr/J, NOD mice (The Jackson Laboratory, 
Bar Harbor, ME, USA), and Foxp3RFP reporter mice (30), kindly 
provided by S. Huber, were housed and maintained under specific 
pathogen-free conditions. Mice were mated and the presence of a 
vaginal plug was considered day 0.5 of pregnancy (E0.5). On day 
18.5 (E18.5) mice were treated by i.p. injection of 0.1 mg beta-
methasone (Sigma-Aldrich, Germany) in PBS or vehicle control 
(PBS). When indicated, 4- to 5-week-old animals were given 
0.1  mg betamethasone i.p. or vehicle control (PBS) 24  h prior 
to organ harvesting. All animal experiments were performed in 
accordance with national and institutional guidelines on animal 
care and ethics.
Flow cytometry
Thymi, lymph nodes and spleens were harvested and single-cell 
suspensions prepared by mechanical disruption and filtering 
through a 70 µm nylon mesh. Red blood cells were lysed when 
necessary and Fc receptors were blocked using anti-CD16/32 Abs 
prior to staining. Anti-mouse Abs used in this study were: anti-
CD3e eFluor 450 (500A2), anti-CD4 APC-eFluor 780 (RM4-5) 
and anti-CD8α PE-Cy7 (53-6.7) from eBioscience (San Diego, 
CA, USA); anti-CD4 FITC (RM4-5), anti-CD4 BV421 (GK1.5), 
anti-CD8α PerCP-Cy5.5 (53–6.7), anti-CD25 PE (3C7), and 
anti-TCRβ chain PerCPCy5.5 (H57-597) from BioLegend (San 
Diego, CA, USA), and anti-CD3ε FITC (145-2C11) from BD 
Biosciences (San Jose, CA, USA).
Analysis of TCR Vβ usage was performed using 15 FITC-
conjugated monoclonal antibodies recognizing the TCR chains 
Vβ2, 3, 4, 5.1/5.2, 6, 7, 8.1/8.2, 8.3, 9, 10b, 11, 12, 13, 14, and 17a 
TCRs (BD Biosciences, San Jose, CA, USA). The percentage of 
Vβ+ cells was determined in each subset after gating on CD4+, 
CD8+, and DN cells.
Data were collected on a Flow Cytometer (FacsCanto II, BD 
Biosciences, San Jose, CA, USA) and analyzed using FlowJo 
Software (Tree Star, Ashland, OR, USA). Cell sorting of thymocyte 
populations was performed on a FACS Aria IIIu (BD Biosciences, 
San Jose, CA, USA) carried out by the FACS sorting Core Unit of 
the University Medical Center Hamburg-Eppendorf.
Thymocyte sensitivity to Betamethasone
One million thymocytes from 5-weeks-old untreated C57B1/6J 
mice were cultured in RPMI-1640 (Gibco, CA, USA) in a 96-well 
round bottom plate (Thermo Fisher Scientific, Germany) and 
incubated with increasing concentrations of betamethasone 
(0.1–100  nM) with or without the addition of 1  µg/ml mife-
pristone (RU486, Sigma-Aldrich). After 16 h at 37°C, cells were 
harvested, washed with 1 × Annexin V Binding Buffer (Exbio, 
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Czech Republic) and subsequently stained for linage markers 
(CD3, CD4, CD8, CD25). For detection of dead and apoptotic 
cells, Dead Cell Stain-Pacific Orange (Invitrogen, CA, USA) and 
Annexin V FITC (BD Biosciences, San Jose, CA, USA) were used 
according to the manufacturer’s instructions.
autologous Mixed lymphocyte  
reaction (aMlr)
Pooled single-cell suspensions from inguinal, axillary, brachial, 
lumbar, and superficial cervical lymph nodes were stained 
with the cell proliferation dye eFluor 670® (eBioscience, San 
Diego, CA, USA) in order to differentiate proliferating and 
non-proliferating cells. Shortly, lymph node cells were washed 
with PBS and resuspended in 2 µM eFluor 670® dye in PBS for 
10  min at 37°C in the dark. Labeling was stopped by adding 
4–5 volumes of cold complete medium (RPMI 1640, 10% 
FCS, 1% penicillin/streptomycin, 2  mM l-glutamine, 50  µM 
2-Mercaptoethanol) and incubated on ice for 5  min. Labeled 
cells were then cultured in complete medium in the presence 
or absence of IL-2 (100  U/ml). Cells were plated at 1 ×  105/
well in a 96-well plate (Thermo Fisher Scientific, Germany) 
for up to 5 days at 37°C in 5% CO2. After 3, 4, and 5 days of 
culture, lymph node cells were collected, washed with PBS and 
stained with Dead Cell Stain-Pacific Orange and anti-TCRβ 
chain PerCPCy5.5, anti-CD4 APC-eFluor 780, and anti-CD8α 
PE-Cy7 antibodies. The proliferation of CD4+, CD8+, and DN 
cells was evaluated according to eFluor dilution measured by 
flow cytometry (FacsCanto II, BD Biosciences).
Disease scoring
MRL/lpr Mice
Organ weights were measured and weight index (mg/g body 
weight) of lymphoid organs (spleen and lymph nodes) was calcu-
lated as follows: organ weight/body weight × 1,000.
Measurement of Double-Stranded (ds) DNA Autoantibodies
Blood samples were collected every 2 weeks starting at 6 weeks of 
age and serum autoantibodies specific for dsDNA were measured 
by enzyme-linked immunosorbent assay (ELISA). 96-well plates 
were coated with 5 µg/ml calf thymus dsDNA (Sigma-Aldrich) at 
4°C overnight. Plates were blocked for 2 h with 1% BSA in PBS 
followed by incubation with diluted mouse serum for 2 h at RT. 
Bound anti-dsDNA autoantibodies were detected with a 1:2,000 
diluted sheep anti-mouse IgG-HRP (Amersham, UK) (2 h, RT), 
and peroxidase reaction was developed using 2,2′-Azino-bis(3-
ethylbenzothiazoline-6-sulfonic acid) diammonium salt (Sigma-
Aldrich, Germany). Absorbance was measured at 405 nm using 
a multilabel plate reader (Victor3, PerkinElmer, MA, USA), data 
were analyzed using Prism software (GraphPad Software, La Jolla, 
CA, USA).
Measurement of Proteinuria
Mice were housed in metabolic cages for urine collection for 
2 h every 2 weeks starting at 6 weeks of age. Albuminuria was 
determined by ELISA (Mouse Albumin ELISA Quantitation Set; 
Bethyl Laboratories, Inc.).
Non-Obese Diabetic (NOD) Mice
Starting at 10  weeks of age, adult mice were monitored daily 
for urine glucose using Glucocard strips (Menarini, Barcelona, 
Spain), until 25 weeks of age. Mice with glycosuria were confirmed 
diabetic when the blood glucose level was >300 mg/dl. The degree 
of immune cell infiltration in the islets (insulitis score) was deter-
mined at the end of the study in all non-diabetic mice. Briefly, 
pancreata were snap frozen in an isopentane/cold acetone bath. 
Cryosections of 5 µm were obtained at non-overlapping levels, 
stained with hematoxylin and eosin (H&E), and analyzed by two 
independent investigators in a blind fashion. A minimum of 40 
islets per animal was analyzed. Insulitis was scored as described 
elsewhere (31): 0 = no insulitis; 1 = peri-insular inflammation; 
2 = infiltration below 25%; 3 = infiltration 25–75%; 4 = infiltra-
tion above 75%.
EAE Mouse Model
For induction of EAE, C57BL/6J mice were immunized s.c. with 
200  µg MOG35–55 peptide (Schafer-N, Copenhagen, Denmark) 
in complete Freund’s adjuvant (Difco Laboratories, LI, USA) 
containing 4  mg/mL Mycobacterium tuberculosis (Difco). In 
addition, 200  ng pertussis toxin (Calbiochem, San Diego, CA, 
USA) was injected i.v. on the day of immunization and 48  h 
later. Animals were scored daily for clinical signs by the follow-
ing system: 0 = no clinical deficits; 1 = tail weakness; 2 = hind 
limb paresis; 3 = partial hind limb paralysis; 3.5 = full hind limb 
paralysis; 4 = full hind limb paralysis and forelimb paresis; and 
5 = premorbid or dead. Animals reaching a clinical score ≥ 4 had 
to be killed according to the regulations of the Animal Welfare 
Act. Investigators were blinded for prenatal treatment during the 
experiments.
gene expression analysis
RNA was extracted from sorted T cell subsets or from thymocytes 
after in vivo or in vitro treatment using the RNeasy Mini Plus kit 
(QIAGEN, Hilden, Germany) and cDNA was synthesized with 
the M-MLV Reverse Transkriptase kit (Invitrogen). TaqMan 
gene expression assay (LifeTechnologies, CA, USA) was used 
to detect GAPDH (Hs02758991_g1) expression. 18S and FoxP3 
expression were determined using SYBR® green and following 
primers: 18S forward: 5′-CGGCTACCACATCCAAGGAA-3′ 
18S reverse: 5′-GCTGGAATTACCGCGGCT-3′; FoxP3 forward: 
5′-GGCCCTTCTCCAGGACAGA-3′ FoxP3 reverse: 5′-GCTG 
ATCATGGCTGGGTTGT-3′.
statistics
Statistical analysis of TCR Vβ chain usage was performed with 
Matlab R2016b (The Mathworks). The fractions of positive cells 
for each Vβ chain, as well as the remaining fraction of cells that was 
not positive for any of the measured Vβ chains (other Vβ), were 
log or square-root transformed to obtain normally distributed 
data. Using N-way ANOVA, the Vβ chain fractions for each cell 
type were correlated to treatment and possible interaction terms, 
with correction for litter size and subject nested within treatment. 
Upon reaching statistical significance, pairwise comparison with 
Fisher’s least significant difference correction was performed 
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to identify which Vβ chain(s) were differently expressed upon 
treatment. For calling statistical significance, alpha of 0.05 was 
applied in all analyses.
Additional statistical analysis, including unpaired Student’s 
t-test, Gehan–Breslow–Wilcoxon test, and Mantel–Cox test were 
performed with GraphPad Prism Software (La Jolla, CA, USA) 
and are indicated in the corresponding figure legends. *P < 0.05, 
**P < 0.01, ***P < 0.001, and ****P < 0.0001.
study approval
This study was carried out in accordance with the recommen-
dations of the Declaration of Helsinki for animal experimental 
investigation and the Principles of Laboratory Animal Care (NIH 
pub.85–23 revised 1985). The protocol was approved by the local 
animal ethics committees (ethical approval 119/13 and 122/12 
obtained from the state authority of Hamburg, and DMAH8948 
obtained from the Generalitat de Catalunya).
resUlTs
Prenatal glucocorticoid Treatment results 
in apoptosis of DP Thymocytes in the 
Mrl/lpr Offspring
We have previously shown in C57BL/6J mice that prenatal 
betamethasone treatment causes a profound reduction in the 
thymic volume and cell numbers in the offspring (16). The 
question that arises is if the massive death and subsequent 
accelerated replenishment of the thymus has consequences 
upon T  cell repertoire selection and immunity later in life. 
To explore this, we took advantage of the MRL/MpJ-Faslpr 
(hereafter referred to as MRL/lpr) autoimmunity-prone mouse 
strain, which spontaneously develops lupus-like glomerulo-
nephritis and vasculitis as result of autoantibody production 
and immune complex deposition (32). In this strain, we first 
sought to confirm the effects of prenatal glucocorticoid treat-
ment on the thymus. After treating the pregnant dams (E18.5) 
with betamethasone (Figure  1A), at postnatal day 1 (PND1) 
we did not observe any difference in the weight of the pups 
(Figure  1B), but a drastic reduction in the number of living 
thymocytes (Figure 1C). Not surprisingly, thymocyte loss was 
caused by a massive reduction in the CD4+CD8+ DP compart-
ment and, as a consequence, a compensational increase in the 
frequency of DN cells (Figures 1D,E) could be observed. This 
effect was transient, since in the adult offspring the percentage 
of DP thymocytes was similar in both groups (not shown). 
Figure  1E shows a direct comparison of the composition of 
the thymocyte compartment in a sham- (upper row) vs. a 
betamethasone-treated (lower row) animal. The density plot in 
the right panels demonstrates the shift from maximal represen-
tation of DP cells in the untreated animals to a maximum of DN 
cells in the animals treated with betamethasone. Importantly, 
the range of DP cell loss within a litter was highly variable, with 
some animals displaying marginal effects while others have 
nearly lost the DP compartment (Figure 1D). This variation is 
likely the result of different exposure of each individual fetus 
to betamethasone (16). The frequencies of CD4SP and CD8SP 
cells remained similar, although we could notice a reduction in 
absolute cell counts (not shown).
Prenatal Betamethasone Treatment leads 
to changes in the T cell repertoire of 
Mrl/lpr Offspring
We next asked if the massive perinatal thymocyte death had 
long lasting consequences on the peripheral T cell compartment. 
While the MRL strain is prone to autoreactivity, the defect in fas 
(lpr, lymphoproliferation) leads to uncontrolled expansion and 
accumulation of autoreactive cells in the peripheral lymphoid 
organs, and accelerates, rather than initiates, disease (33). These 
autoreactive cells harbor the phenotype CD3+B220+CD4−CD8− 
(DN T  cells), and steadily increase with disease progression to 
become the most abundant subset in spleen and lymph nodes. 
Importantly, the TCR Vβ usage of public clones in the enlarged 
lymph nodes and in T cells infiltrating the kidneys of diseased 
animals is limited to a few families, including Vβ2, Vβ6, Vβ8.2, 
Vβ8.3, and Vβ10, underlining their pathogenic relevance (34–36). 
To assess if prenatal glucocorticoid treatment had an effect on the 
autoimmune repertoire, we performed flow cytometric analysis 
of TCR Vβ chain usage in peripheral CD4+, CD8+ and DN T cells 
of young (5- to 7-week old) and aged (15- to 17-week old) off-
spring of mothers treated with vehicle or betamethasone. While 
the frequencies of CD4+, CD8+, and DN T  cells at 5–7  weeks 
of age, before appearance of disease symptoms, were similar in 
both groups, accumulation of DN T  cells in the older animals 
was clearly more prominent in the group that had received beta-
methasone prenatally (Figures 2A,B). Moreover, analysis of Vβ 
chain usage on the different T cell subsets indicated a bias in TCR 
receptor Vβ expression in these mice, with higher representation 
of the potentially autoreactive Vβ2- (7.97 vs 8.95%, P = 0.0564), 
Vβ8.1/8.2- (10.91 vs 12.85%, P =  0.0379), and Vβ10b- (1.97 vs 
2.85%, P  =  0.0113) expressing DN T-cells in young animals 
(5–7  weeks) (Figures  2C,E) and further differences in the fre-
quency of Vβ5.1 CD4+ and CD8+ cells, Vβ11 in CD4+ T  cells, 
and Vβ12 in CD4+ T and DN T cells (Table S1 in Supplementary 
Material). Similarly, the TCR Vβ usage in MRL/lpr animals with 
advanced disease (at 15–17 weeks of age) was also biased, with 
differences in the frequency of Vβ14 (7.46 vs 8.46%, P = 0.0114) 
CD8+ T  cells and, as in young animals, in the disease-relevant 
Vβ10b (4.78 vs 6.18%, P = 0.0389) bearing DN cells (Figures 2D,F; 
Table S2 in Supplementary Material).
We next sought to determine whether the changes observed in 
the TCR Vβ repertoire resulted in a higher proliferation, which 
would reflect the presence of more autoreactive cells. For this, 
we performed AMLR to measure proliferation of autoreactive 
T  cells in response to endogenous antigens. While no external 
TCR stimulus was given, IL-2 was added to the cultures to sup-
port the incipient proliferation of the few autoreactive precursors. 
Although not significant, our data show higher proliferation rates 
of both CD4+ and CD8+ cells in the betamethasone-exposed 
animals (Figure  2G). As expected, DN cells showed maximal 
proliferation, and no differences were found between the treated 
and non-treated groups, since the accumulating DN cells are 
chronically activated in both groups.
FigUre 1 | Loss of double-positive (DP) thymocytes in the offspring of MRL/lpr mice after prenatal betamethasone treatment. (a) Schematic representation of the 
MRL/lpr mouse model. (B) Body weight from prenatally betamethasone (Bet) and vehicle-treated (PBS) MRL/lpr mice (n = 42–44 per group, male and female). (c) 
Total number of thymocytes (n = 10–11 per group, male). (D) Frequency of CD4−CD8− double-negative (DN), CD4+CD8+ DP, and mature CD4+ and CD8+ 
single-positive (SP) thymocytes (n = 8–10 per group, male). (e) t-SNE representation of the surviving cells in the thymic compartment after prenatal betamethasone 
treatment according to the expression of CD3, CD4, and CD8. Each dot represents a cell, and the colors show levels of expression of the indicated markers. The 
plots show one representative animal per group. The rightmost plots display the cell abundance (density) for each population. All analyses were performed at 
postnatal day 1 (PND1). Unpaired Student’s t-test was used for statistical analysis, **P < 0.01 and ***P < 0.001.
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The lpr defect in this mouse strain leads to a progressive 
enlargement of the lymphoid organs, enhancing the disease phe-
notype of the MRL strain (33). Therefore, we would expect that a 
T cell repertoire biased toward more autoreactivity would result 
in larger lymphoid organs. In agreement with increased amounts 
of pathogenic TCR Vβ families and enhanced T  cell prolifera-
tion, the spleens and lymph nodes were considerably larger in the 
animals whose mothers had been treated with betamethasone 
(Figures  2H,I), supporting the concept of a more autoreactive 
T  cell repertoire. However, a higher frequency of autoreactive 
T cells and enlarged lymphoid organs did not translate in acceler-
ated course of disease, as assessed by the levels of dsDNA autoan-
tibodies (Figure 2J) and proteinuria (Figure S1 in Supplementary 
Material) from 6 to 16 weeks of age, which were similar in both 
groups. Of note, prenatal betamethasone treatment resulted in a 
transiently lower body weight (Figure 2K) and higher production 
FigUre 2 | Continued 
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Long-term effects of prenatal steroid treatment in MRL/lpr offspring. Frequencies of spleen T cell subsets CD4+, Treg cells, CD8+, and DN cells at (a) 5–7 weeks and 
(B) 15–17 weeks of age (n = 11–13 per group, male and female). (c,D) T cell receptor (TCR) Vβ chain usage among CD4+, CD8+, and DN splenocytes at  
(c) 5–7 (n = 11–12 per group, male and female) and (D) 15–17 weeks of age (n = 13 per group, male and female) was assessed by flow cytometry. Each of the 15 
analyzed TCR Vβ chain families is represented by a segment proportional in size to its frequency (which on average cover between 61 and 91% of all cells within the 
subsets, the segment “other Vβ” indicates Vβ chain expression not covered by our panel of TCR Vβ chain-specific Abs). Segments marked with an asterisk differ 
statistically significant between the groups (PBS or Bet), framed segments indicate TCR Vβ chains important for autoimmune disease in MRL/lpr mice. (e) Detailed 
results for the relevant TCR Vβ2, Vβ8.1/8.2, and Vβ10b in DN spleen cells at 5–7 weeks of age. (F) Detailed results for the relevant TCR Vβ10b in DN spleen cells at 
15–17 weeks of age. N-way ANOVA was used for statistical analysis of TCR Vβ chain usage. (g) Proliferation of autoreactive CD4+, CD8+, and DN cells from female 
MRL/lpr mice (n = 3–4 per group at 6–8 weeks). Pooled lymph node cells (1 × 105) were cultured in the presence of IL-2 (100 U/ml) without the addition of 
exogenous TCR stimulation for 3–5 days. Extent of cell proliferation was analyzed by flow cytometry based on eFluor 670 dilution. Values are expressed as 
mean ± SEM. (h–K) Disease parameters in MRL/lpr mice: (h) Size of spleen at 15 weeks of age. Effect of prenatal betamethasone treatment on (i) spleen 
(n = 16–19 per group) and lymph node (i = inguinal, n = 10–14 or a&b = axillary and brachial, n = 10–11 per group) weights and indices (mg/g body weight), (J) 
serum levels of dsDNA autoantibodies (n = 7–28 per group and time point), and (K) body weight (n = 9–29 per group and time point). Unpaired Student’s t-test was 
used for statistical analysis; *P < 0.05 and **P < 0.01.
FigUre 2 | Continued
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of ds-DNA specific IgG autoantibodies (Figure 2J) at 6 weeks of 
age, but this difference disappeared soon after. Thus, prenatal 
treatment of the pregnant females with betamethasone elicits 
drastic thymocyte death in the postnatal thymus, which results 
in persistent changes in the TCR repertoire promoting the expan-
sion of autoreactive Vβ families.
Prenatal Betamethasone Protects from 
T1D Development in nOD Mice
Despite the critical role of T cells in the initiation of autoimmun-
ity in MRL/lpr mice, other mechanisms such as the production 
of pathogenic autoantibodies and renal immune-complex 
deposition leading to complement activation, contribute fun-
damentally to disease progression. Therefore, we turned to a 
second model of autoimmunity with a more direct involvement 
of T cells in the immune pathogenesis, the NOD mouse model 
for T1D to assess persisting effects of prenatal betamethasone 
treatment. This spontaneous model of autoimmune diabetes is 
characterized by the activation of autoreactive T  cells and the 
destruction of insulin producing beta-cells in the pancreas. 
After prenatal administration of vehicle or betamethasone to 
non-diabetic females (E 18.5), glucose levels were measured in 
the female offspring for the occurrence of T1D until 25 weeks of 
age (Figure 3A). Surprisingly, we found that fetal glucocorticoid 
exposure was protective against the development of T1D in 
females (Figure 3B). At 25 weeks of age, only 25% of the NOD 
females in the control group were disease-free, while in the 
betamethasone treatment group it was 78%. Moreover, T1D onset 
was delayed in the treated group (from 14 weeks of age) when 
compared to control mice (from 11 weeks of age), consistently 
with the protective effect of the drug. There were no differences 
between the two groups in the frequencies of CD4+, Treg cells, 
CD8+, or CD3+ DN spleen cells at 6 weeks of age (Figure 3C). We 
next investigated whether the different incidence of disease could 
be traced to changes in the TCR Vβ repertoire. In the NOD mice, 
the most commonly found TCR Vβ chains in T cells infiltrating 
the pancreas are Vβ4 (37), and Vβ12 (38, 39), followed by Vβ8.1, 
Vβ2, and Vβ6 (40, 41). Our TCR Vβ usage analysis revealed that 
Vβ12 (6.71 vs. 5.45%, P = 0.0077) CD4+ T cells, and Vβ4 (2.66 vs. 
2.14%, P = 0.0683) and Vβ6 (9.28 vs. 7.39%, P = 0.0124) CD8+ 
T cells were underrepresented in the spleen of the female NOD 
mice whose mothers received betamethasone (Figures  3D,E; 
Table S3 in Supplementary Material). This lower frequency of 
pathogenic TCRs was reflected in the lower degree of immune cell 
infiltration in the pancreas of animals that had not yet developed 
T1D at 25 weeks of age, determined in a second mouse cohort 
(Figures 3F–H). Here, the incidence was somewhat lower in both 
groups, but still 46% of sham-treated females were disease-free at 
25 weeks, while 62% of the betamethasone-treated had normal 
glucose levels (P = 0.0847, Figure S2 in Supplementary Material). 
Therefore, we conclude that a bias in the T cell repertoire caused 
by prenatal glucocorticoid treatment contributes to protection 
from T1D in the NOD mice.
Prenatal Betamethasone Does not induce 
long lasting changes in the Treg cell 
compartment
In addition to changes in TCR Vβ usage, another possibility that 
could affect development of autoimmunity is the quantity or 
quality of Treg cells. Treg cells are less sensitive to glucocorticoid 
challenge than conventional CD4+ cells (42, 43). However, it is 
not known if prenatal treatment with betamethasone results in 
enrichment of Treg cells in the newborn and, more importantly, if 
there are consequences for the peripheral Treg cell compartment 
later in life. In a first set of experiments we exposed thymocytes 
from 6  weeks old (not prenatally treated) C57BL/6J mice to 
increasing concentrations (0.1–100 nM) of betamethasone in vitro 
and measured the survival of Treg cells compared to conventional 
CD4+ T cells. We used mifepristone (RU486), a synthetic steroid 
with potent anti-glucocorticoid properties, to confirm the speci-
ficity of the betamethasone effects. We found that the relative 
frequency of surviving CD4+CD25+ SP thymocytes (which in the 
naïve mice are considered Treg cells) increased in response to 
betamethasone in a dose-dependent manner, and this effect was 
completely inhibited by the addition of RU486 (Figure 4A). More 
than a threefold increase in the frequency of Treg cells compared 
to the untreated controls was achieved at 10 nM (Figure 4A). In 
contrast, conventional CD4+ single-positive thymocytes did not 
significantly change in proportion with increasing concentra-
tions of betamethasone (Figure 4B). To confirm that it is indeed 
FigUre 3 | Prenatal steroid treatment reduces insulitis and the incidence of T1D in NOD mice. (a) Schematic representation of the NOD mouse model.  
(B) Percentage of T1D-free NOD mice during 25 weeks of follow-up (n = 16–18 females per group). Gehan–Breslow–Wilcoxon test was used for statistical analysis. 
(c) Frequency of CD4+, Treg cells, CD8+, and DN splenocytes from female NOD mice at 6 weeks (n = 9–12 per group). (D) Comparison of Vβ chain usage between 
NOD offspring from betamethasone- (Bet) and sham-treated (PBS) dams at 6 weeks of age (n = 9–12 per group, female). Each T cell receptor (TCR) Vβ chain 
among CD4+ and CD8+ T cells is represented by a segment proportional in size to its frequency (which on average cover between 55 and 78% of all cells within the 
T cell subsets, the segment “other Vβ” indicates Vβ chain expression not covered by our panel of TCR Vβ chain-specific Abs). Segments marked with a star differ 
statistically significant between the groups (PBS or Bet), framed segments indicate TCR Vβ chains important for autoimmune disease in NOD mice. (e) Detailed 
results for the relevant TCR Vβ12 in CD4+ and TCR Vβ4 and Vβ6 in CD8+ spleen cells. N-way ANOVA was used for statistical analysis of TCR Vβ chain usage.  
(F) Representative H&E stained sections of pancreata from male and female T1D-free mice at sacrifice (25 weeks). (g) Insulitis score and (h) percentage of islets 
(presented as degree of infiltration: 0 = no insulitis, 1 = peri-insular inflammation, 2 = infiltration < 25%, 3 = infiltration 25–75%, 4 = infiltration > 75%) from 
non-diabetic male and female (n = 3 per group) NOD mice. Unpaired Student’s t-test was used for statistical analysis, *P < 0.05 and **P < 0.01.
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FigUre 4 | Treg precursor cells are less sensitive to betamethasone than conventional CD4+ cells. (a) Percentage of Treg cells after in vitro treatment of thymocytes 
(C57BL/6J) with increasing concentrations of betamethasone (0.1–100 nM) in the presence or absence of mifepristone (RU486) for 16 h. (B) Cell viability of Treg 
cells and conventional CD4 single-positive T cells is displayed as fold change in comparison to the negative control (no betamethasone). (c) Expression levels of 
Foxp3 mRNA in thymocytes after in vitro treatment with betamethasone (0–100 nM) for 16 h. Untreated thymocytes were used as calibrator. (D) Frequency of 
surviving Treg cells in thymocytes of 5-week-old female C57BL/6J mice (n = 5 per group) 24 h after injection of 0.1 mg betamethasone or PBS. (e) Frequency of 
Treg precursor cells in double-positive or (F) Treg cells in CD4SP thymocytes from the offspring of prenatally treated dams (n = 5–7 per group) at postnatal day 0 
(PND0). (g) Frequency of Treg (n = 15 per group), and (h) frequency of Neuropilin-1 positive (tTreg cells) and negative (pTreg cells) cells (n = 7–11 per group) in 
splenocytes at 5–7 weeks of age after prenatal betamethasone or vehicle treatment. Unpaired Student’s t-test was used for statistical analysis, *P < 0.05, 
**P < 0.01, and ****P < 0.0001.
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the Treg cell subset the one increasing, we performed RT-PCR 
on the cultured cells and found increased Foxp3 expression at 
higher betamethasone concentration (Figure 4C). We obtained 
similar results when thymocytes derived from untreated Foxp3RFP 
reporter mice were treated with betamethasone and Foxp3 
expression could be monitored by flow cytometry (Figure S3 in 
Supplementary Material). To test the effects of glucocorticoids on 
the frequency of Treg cells in vivo, we treated 6 weeks old mice 
i.p. with 0.1 mg betamethasone. Analysis of the thymus 24 h post-
treatment revealed a net increase in CD4+CD25+ in the surviving 
cells (Figure 4D). Finally, to find out if prenatal betamethasone 
exposure has an effect on the frequency of neonatal Treg cells, 
we treated pregnant females and analyzed Treg precursor cells 
in the DP thymocytes and in the CD4SP subpopulations in the 
offspring at postnatal day 0. As shown in Figure 4E, we could 
detect an increased frequency of DP CD25+ Treg precursor cells 
and a slightly elevated proportion of CD4+CD25+ thymic-derived 
Treg cells 24  h post-treatment (Figure  4F). This neonatal bias, 
however, did not persist until adulthood, since the percentage 
of Treg cells in the spleen of animals at 5–7  weeks of age was 
similar in both groups (Figure  4G). Moreover, no differences 
were observed in the expression of neuropilin-1 (Figure 4H) or 
CD62L (not shown), indicating similar percentages of thymic and 
peripherally induced Treg cells (44), and similar levels of activa-
tion in both groups. Proliferation and inflammatory cytokine 
production of spleen T  cells at this age was also comparable 
in both groups (not shown). Our data demonstrate that Treg 
thymocyte precursor cells are less sensitive than conventional 
CD4+ precursors to prenatal administration of betamethasone, 
resulting in a transient increase in the frequency of Treg precur-
sor cells after birth. However, these differences are not persisting, 
and do not elicit changes in the future Treg cell compartment.
Prenatal Betamethasone has no effect  
on Disease in the context of a highly 
restricted Pathogenic repertoire
In the two models of autoimmune disease that we have analyzed, 
disease develops spontaneously, and the TCR repertoire of the 
pathogenic cells is oligoclonal. In both cases, we have shown 
that antenatal betamethasone treatment elicits changes in the 
TCR Vβ usage affecting the autoreactive T  cell repertoire. To 
address if indeed glucocorticoid-induced changes in the TCR 
repertoire are responsible for this effect, we took advantage of 
a model in which only few TCRs are engaged in the pathogenic 
response, namely EAE induced by MOG35–55 peptide. In contrast 
to the more polyclonal response in the lupus-prone MRL/lpr 
mouse and in the NOD mouse model, in this induced model of 
autoimmunity, half of the CNS infiltrating cells bear Vβ8.1 or 
Vβ8.2 (45–47). We therefore treated pregnant C57BL/6J females 
with betamethasone at E18.5, and let the offspring develop 
normally, until injection of the MOG peptide at 6  weeks of 
age (Figure 5A). After disease induction, mice were examined 
daily and scored for clinical symptoms of disease for 30 days. 
FigUre 5 | Prenatal betamethasone does not alter the onset or the course of experimental autoimmune encephalomyelitis (EAE) despite changes in the T cell 
receptor (TCR) Vβ repertoire. (a) Schematic representation of the EAE mouse model. (B) EAE clinical scores and (c) survival of C57BL/6J mice (n = 9–11 per 
group, male and female) after MOG35–55 EAE induction in offspring of dams prenatally treated with betamethasone or PBS. Statistical analysis of survival was 
performed with Mantel–Cox test. (D) Comparison of Vβ chain usage between C57BL/6J offspring from betamethasone- or sham-treated mothers. Each TCR Vβ 
chain among CD4+ and CD8+ splenocytes is represented by a segment proportional in size to its frequency (which on average cover between 74 and 84% of all 
cells within the T cell subsets, the segment “other Vβ” indicates Vβ chain expression not covered by our panel of TCR Vβ chain-specific Abs). Segments marked with 
a star differ statistically significant between the groups (PBS or Bet), framed segments indicate TCR Vβ chains important for autoimmune disease in EAE mice. Data 
obtained at 5–7 weeks (n = 15 per group, male and female). (e) TCR Vβ chain usage represented as percent of change to negative control (PBS) ± SEM. N-way 
ANOVA was used for statistical analysis of TCR Vβ chain usage, *P < 0.05, **P < 0.01, and ***P < 0.001.
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No differences could be seen in disease onset, clinical score or 
survival between the animals whose mothers had been treated 
with betamethasone or with vehicle (Figures  5B,C). Analysis 
of the TCR repertoire revealed significant changes in Vβ chain 
usage between the two groups, namely affecting Vβ5.1/5.2 (2.73 
vs. 3.27%, P = 0.0004) and Vβ7 (2.24 vs. 1.99%, P = 0.0315) in 
CD4+ and Vβ7 (5.79 vs. 5.22%, P =  0.0040) in CD8+ T  cells. 
However, the frequency of the disease-relevant Vβ8.1/8.2 chains 
remained unchanged (Figures 5D,E; Table S4 in Supplementary 
Material). Our data show that prenatal betamethasone is not 
altering the highly restricted pathogenic TCR repertoire in EAE, 
and—consequently—the disease course is similar in both groups 
of mice.
DiscUssiOn
Glucocorticoids are administered to pregnant women at risk 
of preterm delivery. A single course of betamethasone reduces 
morbidity related to acute respiratory distress in the neonate, 
without apparent short-term side effects (6). However, a com-
plete absence of a thymic shadow in X-ray images has been 
reported for all newborns that received prenatal dexamethasone 
treatment, while in the majority of healthy gestation-week 
matched untreated controls the thymus was visible (48). This 
condition is transient, since control X-rays over the first 4 weeks 
of life showed a progressive enlargement of the thymic gland 
(48). To explore possible long-term consequences of prenatal 
glucocorticoids in humans is a challenge, since women are 
treated upon symptoms of pre-term birth, which may happen 
at different time points of pregnancy, and the time span between 
treatment and birth can also be highly variable. It is therefore 
not surprising that analysis of cord blood parameters has not 
yielded conclusive results [reviewed in Ref. (49)]. Interestingly, 
epidemiological studies in much larger cohorts indicate an 
increased risk for infection in the neonate (50), and for asthma 
(51) and T1D (52) in young children that received prenatal 
steroid treatment.
For the reasons mentioned above in relation to human studies, 
we decided to use mouse models to explore possible long-term 
consequences of prenatal steroids upon the immune system. One 
dose of betamethasone equivalent to what is given in human 
pregnancy was injected to the dams before delivery. This dose 
is the minimum dose that showed improved lung maturation 
compared to vehicle in mice (53). Our experiments showed a 
drastic reduction in thymic size and cell numbers after prenatal 
betamethasone in the three mouse strains tested. The thymus 
plays an essential role for the development of a functional and 
self-tolerant TCR repertoire. Positive and negative selection 
events based on TCR avidity for self pMHC, ensure the elimina-
tion of non-functional or autoreactive T cells. Glucocorticoids 
have been shown to regulate the avidity threshold between 
positive and negative selection, and altered glucocorticoid sign-
aling results in a biased T cell repertoire (26–28, 54, 55). Thus, 
it is plausible that an excess of glucocorticoids in a moment of 
active immune development, like the perinatal period, causes 
changes in the T  cell repertoire influencing development of 
autoimmunity.
Autoreactive T  cell clones bearing distinct TCR Vβ chains 
expand in the target organs of autoimmune disease. For instance, 
T cells of the Vβ8.2 family recognizing MOG35–55 are predomi-
nant in the brain of C57BL/6 mice (47), and the repertoire of 
T cells infiltrating the pancreas of the NOD mouse is skewed to 
a limited set of families, including Vβ2, Vβ4, Vβ6, Vβ8.1, and 
Vβ12 (37–41, 56). Interestingly, injection of dexamethasone 
in the first 3  days of life has been shown to exert long-lasting 
effects on the expression of several Vβ genes in rats (57). We thus 
sought to assess the effect of prenatal corticosteroid treatment 
on the TCR Vβ repertoire in two spontaneous mouse models 
of autoimmunity. We decided to use flow cytometry to assess 
TCR Vβ family usage because it allows efficient measurement 
on the different T  cell subsets in individual mice simultane-
ously, without previous cell sorting. Exploiting this strategy, we 
observed that Vβ chains that are relevant for the development of 
T1D in the NOD mouse are underrepresented in the offspring 
of mothers that were treated with betamethasone. For instance, 
we found decreased frequencies of peripheral T  cells bearing 
the Vβ4 in mice whose mothers received betamethasone. Vβ4 
is utilized by all NOD mice in response to a dominant epitope 
on glutamic acid decarboxylase 65, and T cell responses to this 
antigen are already detected in the spleens of young pre-diabetic 
NOD mice (37), suggesting that this is an important epitope of 
the primary response. The oligoclonal pattern of islet infiltrating 
T cells in the NOD model in pre-diabetic mice (40, 41) is a strong 
indication of local antigen-driven expansion of a limited number 
of clonotypes, at least at the start of the disease, before epitope 
spreading. Thus, even subtle changes in the composition of the 
TCR repertoire, if affecting the relevant specificities, are likely to 
influence disease development. Not surprisingly, disease severity 
remained unchanged after prenatal betamethasone treatment 
in MOG-induced EAE, where T cells from the TCR Vβ8.1/8.2 
families, which account for half of the cells infiltrating the cen-
tral nervous system (46), were not affected by prenatal steroid 
treatment.
In contrast to the NOD model, we found that Vβ chains 
known to be expanded in the lymph nodes of MRL/lpr mice 
are more prominent in the offspring of betamethasone-treated 
mothers. In this particular mouse strain, the defect in Faslpr gene 
promotes the accumulation of activated autoreactive cells with 
the CD3+CD4−CD8− DN phenotype in peripheral lymphoid 
organs (33, 58). The expanded population of the abnormally 
proliferating lymph node T cells in MRL/lpr mice is heterogene-
ous, but Vβ gene expression is skewed toward members of the 
Vβ2 and Vβ8 families in the DN population (35, 36, 59, 60). The 
pathogenic nature of Vβ8-bearing T cells is underpinned by the 
lack of disease in animals that have been treated with anti-TCR 
Vβ8 antibodies (61). Our data show that Vβ2, Vβ8.1/8.2 and 
Vβ10b are overrepresented in the DN population in the offspring 
of betamethasone-treated mothers, indicating a larger contingent 
of autoreactive cells in these animals. This is further supported by 
the higher proliferation of CD4+ and CD8+ T cells in the AMLR, 
and the larger size of lymphoid organs. Still, we did not observe 
more severe disease in the treated animals, which is probably due 
to the fact that although autoreactive T  cells contribute to the 
initiation of disease, the underlying causes for the pathogenesis 
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in the MRL/lpr lupus model lie in the activation of complement 
by immune complex deposition in the kidney and blood vessels, 
and inflammatory responses triggered by defects in the clearance 
of dying cells (62, 63).
How do prenatal glucocorticoids exert their effect on the T cell 
repertoire? Using different strategies of glucocorticoid-receptor 
deficiency it has already been shown that diminished glucocorti-
coid signaling can alter the positive and negative selection avid-
ity thresholds, or create “holes” in the TCR repertoire (26–28). 
Indeed, lymph nodes and spleen were smaller and the TCR 
repertoire was less autoreactive in MRL/lpr animals with deficient 
glucocorticoid receptor expression in thymocytes (26), which is 
the opposite effect of what we have observed after prenatal excess 
of glucocorticoids. Mechanistically, this could be due to the ability 
of glucocorticoids to regulate T cell activation-related processes, 
thus influencing the outcome of thymic selection. Another pos-
sibility is that glucocorticoids alter the TCR repertoire by modu-
lating the transcription of endogenous retroviruses encoding for 
superantigens (64). Steroid hormones stimulate the expression of 
HERV-K in human cell lines (65), and a recent study has shown 
that all endogenous retroviral promoters tested responded to 
dexamethasone treatment with changes in activity in more than 
20 mouse strains (66). Since in the process of developing toler-
ance to superantigens the TCR-reactive Vβ chains are partially or 
completely deleted in the thymus (67), glucocorticoid-induced 
changes in the transcription of endogenous retroviruses could be 
the underlying cause for the differences that we find in the periph-
eral TCR repertoire. Indeed, endogenous retroviral sequences 
induced autoreactive T cells when injected into neonate NOD, 
but not C57BL/6 mice (68), highlighting the importance of this 
pathway for the modulation of the T cell repertoire, but also the 
strain-specific effects (66, 69). In humans, reactivation of endog-
enous retroviruses has been associated to several autoimmune 
diseases, including T1D, multiple sclerosis and systemic lupus 
erythematosus [reviewed in Ref. (70)]. For instance, viral particles 
of the human endogenous retrovirus HERV-K have been isolated 
from pancreatic islets of T1D patients, suggesting a possible role 
in the disease (71). HERV-K encodes for a superantigen that can 
efficiently stimulate Vβ7 CD4+ T cells, which are expanded in the 
pancreas of patients with T1D (72, 73). Notably, TCR Vβ7 CD4+ 
precursors were deleted by HERV-K18 in an in  vitro model of 
human negative selection (74), altogether linking glucocorticoid-
induced transcription of endogenous retroviruses, TCR Vβ 
repertoire selection and autoimmunity also in the human system.
The observed disease protection in the NOD model is intrigu-
ing. Obviously, prenatal exposure to glucocorticoids can alter the 
epigenome of the offspring, affecting multiple organs and pathways 
(75). Therefore, in addition to the observed effects on TCR reper-
toire, we cannot discard epigenetic effects on glucose metabolism 
or pancreatic beta cell development as disease modifiers (76), and 
research on this topic is ongoing. Moreover, changes in the micro-
biome are likely to influence immune system development in the 
offspring (77). In this context, prenatal dexamethasone was found 
to induce epigenetic changes affecting genes involved in intestinal 
barrier function, subsequently influencing bacterial colonization 
at two weeks after birth (78). Interestingly, changes in the intestinal 
microbiota or a diet rich in the microbial metabolites acetate and 
butyrate have a profound influence on the development of T1D 
in the NOD mouse by decreasing the frequency of autoreactive 
T cells or boosting regulatory function (79, 80).
Foxp3+ Treg cells constitute another plausible player in disease 
protection. Naturally occurring Treg cells develop in the thymus, 
originating from thymocytes with high affinity for self pMHC 
complexes (81), and are also subjected to the effects of prenatal 
glucocorticoids. In line with published data (42), our results 
obtained from different in  vitro and in  vivo settings show that 
Treg precursor cells are less sensitive to glucocorticoid-induced 
cell death than their non-Treg cell counterparts, and this has 
also been shown for mature Treg cells (43). This could be due to 
several reasons, including an enhancer effect of glucocorticoid 
signaling on foxp3 gene expression (82, 83), or Treg cell genera-
tion driven by intrathymic TGF-β production upon thymocyte 
apoptosis (84). Thus, either by preventing apoptosis of Treg cells 
or by directly inducing Treg cell differentiation, glucocorticoids 
support enhanced Treg cell development, noticeable shortly 
after birth. This effect, however, does not persist into adulthood, 
since we do not see any difference in Treg cell frequencies or 
function (not shown). In line with our data, adult GR-deficient 
animals had normal frequencies of Treg cells in the periphery 
(28). A particular population of Treg cells generated perinatally 
are crucial for the maintenance of tolerance to self-antigens, and 
the presence of these cells prevented insulitis in the NOD mice 
(22). We do not favor the notion that the perinatally generated 
Treg cells are responsible for protection in our model, because if 
prenatal steroids would specifically enhance development of this 
highly protective population, their influence would be noticeable 
not only in the NOD model, but also in the EAE model, which is 
susceptible to even small variations in the Treg cell compartment 
(43). Altogether, we conclude that it is the changes in the TCR 
repertoire and not the effect on Treg cell development what influ-
ences disease susceptibility in the NOD model. Interestingly, a 
recent study showed a beta cell antigen-specific pro-inflammatory 
T-helper cell signature in 6-month-old children who years later 
developed T1D, suggesting early T cell priming in the perinatal 
period (85).
A limitation of our prenatal betamethasone treatment model 
is that not all fetuses are equally affected by prenatal steroid treat-
ment [Figure 1D (16)]. At the time point PND1, the relative fre-
quencies of CD4+CD8+ thymocytes or of granulocytes in spleen 
can be taken as a proxy for the amount of betamethasone that 
the fetus received. At 6 weeks of life, however, it is not possible to 
identify the animals that were only minimally affected by prenatal 
steroids, and therefore they are also included in the analysis. In 
this regard, we believe that the long-term effects of prenatal 
betamethasone might be more prominent than what our results 
show, since they include animals that were very little affected, 
and this will not be the case in human singleton pregnancies. A 
possibility to overcome this problem in the mouse model could 
be to inject betamethasone postnatally, however, the influence 
of the incoming microbiome will probably mask the effects of 
betamethasone. Finally, while our data clearly demonstrate that 
changes in the TCR repertoire alter the course of autoimmun-
ity, additional T  cell-independent mechanisms influencing the 
outcome of disease are not ruled out.
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In this study, we asked whether prenatal exposure to glucocorti-
coids influences the development of autoimmunity later in life. By 
analyzing TCR Vβ usage in two mouse strains that spontaneously 
develop autoimmunity and in the MOG-EAE model, we provide 
evidence that prenatal betamethasone treatment, by changing the 
peripheral T cell repertoire, modifies the autoreactive T cell pool, 
and this may lead to unpredictable variations in the course of 
autoimmune disease, depending on which T cell clonotypes are 
affected. Thus, in spite of the undisputable benefits of prenatal 
glucocorticoids for infants born prematurely, this treatment may 
be associated with long-term effects on immunity, and it should 
be used with caution in cases where the risk of preterm birth is 
only marginal.
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